• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: COVIDIEN 5FR DUAL-LUMEN UVC CATH; CATHETER, UMBILICAL ARTERY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

COVIDIEN 5FR DUAL-LUMEN UVC CATH; CATHETER, UMBILICAL ARTERY Back to Search Results
Model Number 8888160556
Medical Device Problem Code Break (1069)
Health Effect - Clinical Code Foreign Body In Patient (2687)
Date of Event 11/20/2020
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
The complainant indicated that the device will not be returned for evaluation, therefore, a failure analysis is not available, and we are not able to determine the relationship between this device, and the cause for this event.As part of our manufacturing process, all device history records are reviewed, and approved by quality, prior to release of product.If additional information, or the sample is received, the investigation will be re-opened, and responded to accordingly.
 
Event or Problem Description
The customer reported that while checking for resistance, the catheter snapped causing +- 10 cm to be retained within the patient.Additional information provided on 2-dec-2020 stated that the patient had to be referred to a cardiologist in (b)(6) to undergo open heart surgery to remove the catheter.It snapped at the 10cm mark just outside the umbilical cord as they tested for resistance.Additional information provided by the customer on 8-dec-2020 stated that chlorhexidine/saline was used to clean the area prior to insertion.The area was completely dry prior to insertion on (b)(6) 2020 into the uvc.It was secured with 3.0 stitches and to the responder's knowledge it was not difficult to secure.The line was flushed on a regular basis with neocyte infusion/water for injection before insertion, neocyte infusion after insertion.Chlorhexidine/saline was used to clean the cord.Webcol on the hub.The uvc broke on (b)(6) 2020, and the retained uvc was surgically removed on (b)(6) 2020.The device was not replaced.Besides the retainment there was no injury to the patient.Additional medical intervention required was intubation, ventilation, after extubation, oxygen therapy, pericardial and thoracic drains, urinary catheter and central lines inserted.Inotropes, sedation and antibiotic therapy.The patient is currently on room air and establishing suck feeds.The patient's date of birth was (b)(6) 2020, male, birth weight: (b)(6) kg.
 
Additional Manufacturer Narrative
Updated h1: type of reportable event from malfunction to serious injury.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
5FR DUAL-LUMEN UVC CATH
Common Device Name
CATHETER, UMBILICAL ARTERY
Manufacturer (Section D)
COVIDIEN
edificio b20 calle #2 zona fra
alajuela
CS 
MDR Report Key10998506
Report Number3009211636-2020-00729
Device Sequence Number19020851
Product Code FOS
UDI-Device Identifier20884527005182
UDI-Public20884527005182
Combination Product (Y/N)N
Initial Reporter CountrySF
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source company representative,distri
Initial Reporter Occupation Other
Type of Report Initial,Followup
Report Date (Section B) 02/09/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device No Information
Device Expiration Date08/27/2024
Device Model Number8888160556
Device Catalogue Number8888160556
Device Lot Number1926700124
Was Device Available for Evaluation? No
Initial Date Received by Manufacturer 12/01/2020
Supplement Date Received by Manufacturer12/01/2020
Initial Report FDA Received Date12/13/2020
Supplement Report FDA Received Date02/09/2021
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age7 DA
-
-